nature.com search

1 July 2002

Safety and efficacy of STI-571 (imatinib mesylate) in patients with bcr/abl-positive chronic myelogenous leukemia (CML) after autologous peripheral blood stem cell transplantation (PBSCT)

Leukemia 16 , 1220–1228

Rights & permissions

Research | 1 November 2001

Hematologic and cytogenetic remission by STI571 (Glivec) in a patient relapsing with accelerated phase CML after second allogeneic stem cell transplantation

Bone Marrow Transplantation 28 , 721–724

Rights & permissions

Comments and Opinion | 26 September 2003

Efficacy and safety of imatinib mesylate (Glivec™) in combination with interferon-α (IFN-α) in Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph⁺ALL)

Leukemia 17 , 1919–1924

Rights & permissions

Comments and Opinion | 10 September 2003

Serial minimal residual disease (MRD) analysis as a predictor of response duration in Philadelphia-positive acute lymphoblastic leukemia (Ph⁺ALL) during imatinib treatment

Leukemia 17 , 1700–1706

Rights & permissions

Comments and Opinion | 10 September 2003

Molecular monitoring of response to imatinib (Glivec^®) in CML patients pretreated with interferon alpha. Low levels of residual disease are associated with continuous remission

Leukemia 17 , 1687–1694

Rights & permissions

Comments and Opinion | 26 November 2002

Therapy with imatinib mesylate (Glivec) preceding allogeneic stem cell transplantation (SCT) in relapsed or refractory Philadelphia-positive acute lymphoblastic leukemia (Ph+ALL)

Leukemia 16 , 2358–2365

Rights & permissions

Comments and Opinion | 28 October 2002

Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy

Leukemia 16 , 2190–2196

Rights & permissions

Comments and Opinion | 30 August 2002

Early reduction of BCR-ABL mRNA transcript levels predicts cytogenetic response in chronic phase CML patients treated with imatinib after failure of interferon α

Leukemia 16 , 1579–1583

Rights & permissions

Research | 8 December 2005

Imatinib mesylate is effective in children with chronic myelogenous leukemia in late chronic and advanced phase and in relapse after stem cell transplantation

Leukemia 20 , 187–192

Rights & permissions

Research | 11 April 2003

Stable molecular remission induced by imatinib mesylate (STI571) in a patient with CML lymphoid blast crisis relapsing after allogeneic stem cell transplantation

Bone Marrow Transplantation 31 , 611–614

Rights & permissions

Comments and Opinion | 2 October 2003

Dynamics of BCR-ABL mRNA expression in first-line therapy of chronic myelogenous leukemia patients with imatinib or interferon α/ara-C

Leukemia 17 , 2392–2400

Rights & permissions

Comments and Opinion | 23 May 2003

In BCR-ABL-positive cells, STAT-5 tyrosine-phosphorylation integrates signals induced by imatinib mesylate and Ara-C

Leukemia 17 , 999–1009

Rights & permissions

Refine your results by…

Filters

Filter By:

Safety and efficacy of STI-571 (imatinib mesylate) in patients with bcr/abl-positive chronic myelogenous leukemia (CML) after autologous peripheral blood stem cell transplantation (PBSCT)

Hematologic and cytogenetic remission by STI571 (Glivec) in a patient relapsing with accelerated phase CML after second allogeneic stem cell transplantation

Efficacy and safety of imatinib mesylate (Glivec™) in combination with interferon-α (IFN-α) in Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph⁺ALL)

Serial minimal residual disease (MRD) analysis as a predictor of response duration in Philadelphia-positive acute lymphoblastic leukemia (Ph⁺ALL) during imatinib treatment

Molecular monitoring of response to imatinib (Glivec^®) in CML patients pretreated with interferon alpha. Low levels of residual disease are associated with continuous remission

Therapy with imatinib mesylate (Glivec) preceding allogeneic stem cell transplantation (SCT) in relapsed or refractory Philadelphia-positive acute lymphoblastic leukemia (Ph+ALL)

Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy

Early reduction of BCR-ABL mRNA transcript levels predicts cytogenetic response in chronic phase CML patients treated with imatinib after failure of interferon α

Imatinib mesylate is effective in children with chronic myelogenous leukemia in late chronic and advanced phase and in relapse after stem cell transplantation

Stable molecular remission induced by imatinib mesylate (STI571) in a patient with CML lymphoid blast crisis relapsing after allogeneic stem cell transplantation

Dynamics of BCR-ABL mRNA expression in first-line therapy of chronic myelogenous leukemia patients with imatinib or interferon α/ara-C

In BCR-ABL-positive cells, STAT-5 tyrosine-phosphorylation integrates signals induced by imatinib mesylate and Ara-C

Quick links

Refine your results by…

Filters ​

Filter By:

Search

Quick links

Filters